These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 10770911)

  • 1. Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy.
    Kaplan JE; Hanson D; Dworkin MS; Frederick T; Bertolli J; Lindegren ML; Holmberg S; Jones JL
    Clin Infect Dis; 2000 Apr; 30 Suppl 1():S5-14. PubMed ID: 10770911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surveillance for AIDS-defining opportunistic illnesses, 1992-1997.
    Jones JL; Hanson DL; Dworkin MS; Alderton DL; Fleming PL; Kaplan JE; Ward J
    MMWR CDC Surveill Summ; 1999 Apr; 48(2):1-22. PubMed ID: 12412613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Opportunistic infections and other AIDS-defining illnesses in Poland in 2000-2002.
    Podlasin RB; Wiercinska-Drapalo A; Olczak A; Beniowski M; Smiatacz T; Malolepsza E; Juszczyk J; Leszczyszyn-Pynka M; Mach T; Mian M; Knysz B; Horban A
    Infection; 2006 Aug; 34(4):196-200. PubMed ID: 16896577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Approach to opportunistic illness in the HAART era].
    Imamura A
    Nihon Rinsho; 2002 Apr; 60(4):757-62. PubMed ID: 11968784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Highly Active AntiRetroviral Therapy and opportunistic protozoan infections].
    Pozio E
    Parassitologia; 2004 Jun; 46(1-2):89-93. PubMed ID: 15305694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The changing pattern of AIDS-defining illnesses with the introduction of highly active antiretroviral therapy (HAART)in a London clinic.
    Ives NJ; Gazzard BG; Easterbrook PJ
    J Infect; 2001 Feb; 42(2):134-9. PubMed ID: 11531320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pneumocystis carinii pneumonia.
    Schliep TC; Yarrish RL
    Semin Respir Infect; 1999 Dec; 14(4):333-43. PubMed ID: 10638513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. I hear you knockin' (but you can't come in): potent new HIV therapies are shutting out opportunistic infections.
    Fichtenbaum CJ
    Res Initiat Treat Action; 1998 Jul; 4(4):3-7. PubMed ID: 11365645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The rate of serious bacterial infections among HIV-infected children with immune reconstitution who have discontinued opportunistic infection prophylaxis.
    Nachman S; Gona P; Dankner W; Weinberg A; Yogev R; Gershon A; Rathore M; Read JS; Huang S; Elgie C; Hudgens K; Hughes W
    Pediatrics; 2005 Apr; 115(4):e488-94. PubMed ID: 15772172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Opportunistic infections: an update.
    Furrer H; Fux C
    J HIV Ther; 2002 Feb; 7(1):2-7. PubMed ID: 11956497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Altered natural history of AIDS-related opportunistic infections in the era of potent combination antiretroviral therapy.
    Jacobson MA; French M
    AIDS; 1998; 12 Suppl A():S157-63. PubMed ID: 9632998
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prevention of opportunistic infections in the protease inhibitor era].
    Viciana P; Miralles-Martín P; Knobel H; Gatell JM
    Enferm Infecc Microbiol Clin; 1998; 16 Suppl 1():1-10. PubMed ID: 9859614
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pneumonia in HIV-infected patients in the HAART era: incidence, risk, and impact of the pneumococcal vaccination.
    López-Palomo C; Martín-Zamorano M; Benítez E; Fernández-Gutiérrez C; Guerrero F; Rodríguez-Iglesias M; Girón-González JA
    J Med Virol; 2004 Apr; 72(4):517-24. PubMed ID: 14981752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlates of opportunistic infections in children infected with the human immunodeficiency virus managed before highly active antiretroviral therapy.
    Dankner WM; Lindsey JC; Levin MJ;
    Pediatr Infect Dis J; 2001 Jan; 20(1):40-8. PubMed ID: 11176565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. EuroSIDA Study Group.
    Weverling GJ; Mocroft A; Ledergerber B; Kirk O; Gonzáles-Lahoz J; d'Arminio Monforte A; Proenca R; Phillips AN; Lundgren JD; Reiss P
    Lancet; 1999 Apr; 353(9161):1293-8. PubMed ID: 10218526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Update on opportunistic infections.
    Proj Inf Perspect; 1997 Nov; (23):16-7. PubMed ID: 11365373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prophylaxis against Pneumocystis carinii pneumonia among children with perinatally acquired human immunodeficiency virus infection in the United States. Pneumocystis carinii Pneumonia Prophylaxis Evaluation Working Group.
    Simonds RJ; Lindegren ML; Thomas P; Hanson D; Caldwell B; Scott G; Rogers M
    N Engl J Med; 1995 Mar; 332(12):786-90. PubMed ID: 7862183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors for opportunistic illnesses in children with human immunodeficiency virus in the era of highly active antiretroviral therapy.
    Ylitalo N; Brogly S; Hughes MD; Nachman S; Dankner W; Van Dyke R; Seage GR;
    Arch Pediatr Adolesc Med; 2006 Aug; 160(8):778-87. PubMed ID: 16894075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy. Swiss HIV Cohort Study.
    Furrer H; Egger M; Opravil M; Bernasconi E; Hirschel B; Battegay M; Telenti A; Vernazza PL; Rickenbach M; Flepp M; Malinverni R
    N Engl J Med; 1999 Apr; 340(17):1301-6. PubMed ID: 10219064
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidemiology and risk of pulmonary disease.
    Rosen MJ
    Semin Respir Infect; 1999 Dec; 14(4):301-8. PubMed ID: 10638509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.